ERBB2 and breast cancer: In the Impact of Recurrence Score® (RS) result on adjuvant treatment decisions and tumor cell dissemination in ER-positive and HER2-negative patients with early breast cancer (IRMA) trial, RS result and DTC-status were assessed prospectively [19].